Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.46 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997127 | 1.00 | OPRL1 (0.51) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL1508536 | 1.00 | OPRL1 (0.51) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL1746541 | 1.00 | OPRL1 (0.51) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL12014020 | 0.90 | UGT2B17 (0.58) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL5752195 | 0.89 | UGT2B17 (0.51) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL15494638 | 0.84 | POLL (0.41) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL3630215 | 0.84 | POLL (0.41) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL9277764 | 0.84 | POLL (0.41) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL30038859 | 0.83 | UGT2B17 (0.42) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL13517902 | 0.80 | POLL (0.44) | OPRL1KCNH2OPRM1POLLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | GOT2, GOT1, ANXA5 | OPRL1 984/4885KCNH2 3670/4885ADRA2A 1550/4885 |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | OPRL1 722/4885KCNH2 321/4885ADRA2A 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.